Vertex Pharmaceuticals, Inc.

Camil Sayegh

Tiansheng Wang

Jingrong Cao

Brian Ledford

Jon H Come

Suganthini S Nanthakumar

Warren A Dorsch

Elaine B Krueger

Timothy J Senter

Leslie A Dakin

Anne Fortier

Olivier Nicolas

Michael Aaron Brodney

Francois Maltais

Claudio F Sturino

Ales Medek

Yi Shi

Kevin Gagnon

Peter Jamison Rose

Muna Shrestha

Janek Szychowski

Lee Fader

Martine Hamel

Francois Denis

Kan-Nian Hu

Faith Witkos

Stephane Dorich

Stephanie Dorich

The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

Inhibitors of APOL1 and methods of using same

The disclosure provides at least one entity chosen from compounds of Formula (I)

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD). 

Growing community of inventors

Boston, MA, United States of America

Camil Sayegh